Quantum Biopharma Ltd.
Quantum BioPharma is a biopharmaceutical company developing drug candidates for neurodegenerative, inflammatory and metabolic disorders and alcohol misuse. Through its subsidiary Lucid, it conducts research and development on Lucid-MS, a patented drug candidate for multiple sclerosis. It also develops novel formulations intended to treat alcohol misuse in healthcare settings, including hospitals and medical practices. Quantum has licensed its unbuzzd technology, a formulation of natural ingredients, vitamins and minerals intended to support liver and brain function and relieve effects of alcohol consumption, to Unbuzzd and Celly U.S. It earns royalties on sales of products made using the licensed technology. The company also invests in cryptocurrencies as part of its corporate treasury management. Quantum BioPharma is headquartered in Toronto, Ontario, Canada.
No SEC Form 4 filings for $QNTM in the last 30 days.
See all $QNTM insider activity →Quantum BioPharma reported a Q3 Non-GAAP EPS of -$0.06. The company's cash and cash equivalents increased by $1.65 million, or 87%, to $3.56 million as of September 30, 2026, up from $1.91 million at the end of 2025, according to the company's press release.
Quantum BioPharma (QNTM) reported Q3 2026 results, with cash and digital assets totaling $12.22M, up from $4.12M at year-end 2025. Shareholders' equity and total assets also increased, while operating expenses decreased by 32%. The company initiated a Phase 2 trial for Lucid-MS and improved its current and debt-to-equity ratios.
Quantum BioPharma (QNTM) issued 26 Class A shares at C$3.11 each, raising C$80.86 for working capital. Insiders' voting power increased from 57.01% to 68.22%. Further changes require board approval, according to the company.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning QNTM (Quantum Biopharma Ltd.). Coverage has been balanced: 3 bullish, 0 neutral, and 3 bearish.
Recent QNTM coverage spans financial news, earnings and corporate actions.
The loss per share and modest cash increase suggest limited upside; investors may view the result as a disappointment.
The FDA clearance removes a regulatory hurdle and improves the company's cash runway, likely supporting a near‑term price uptick.
Quantum BioPharma (QNTM) issued 26 Class A shares at C$3.11 each, raising C$80.86 for working capital. Insiders' voting power increased from 57.01% to 68.22%. Further changes require board approval, according to the company.
The vote on share consolidation could affect voting power and share count, influencing investor sentiment.
The strategic announcement may improve investor perception of pipeline diversification and funding outlook.
AlphAI scores every news story that mentions QNTM with an AI model for sentiment and relevance, and aggregates insider trades from Quantum Biopharma Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Quantum BioPharma reported a Q3 Non-GAAP EPS of -$0.06. The company's cash and cash equivalents increased by $1.65 million, or 87%, to $3.56 million as of September 30, 2026, up from $1.91 million at the end of 2025, according to the company's press release.
Quantum BioPharma (QNTM) reported Q3 2026 results, with cash and digital assets totaling $12.22M, up from $4.12M at year-end 2025. Shareholders' equity and total assets also increased, while operating expenses decreased by 32%. The company initiated a Phase 2 trial for Lucid-MS and improved its current and debt-to-equity ratios.
Quantum BioPharma (QNTM) issued 26 Class A shares at C$3.11 each, raising C$80.86 for working capital. Insiders' voting power increased from 57.01% to 68.22%. Further changes require board approval, according to the company.
Quantum BioPharma (QNTM) filed a supplement to its meeting circular, clarifying share consolidation rules and voting power caps. The November 10, 2026 meeting will address share consolidation, with fractional shares rounded up or down. The company also plans to cap voting power at 70% if certain conditions are met. Previously submitted proxies remain valid.
Quantum BioPharma (QNTM) is advancing treatments for neurological, metabolic, and alcohol misuse disorders. Its strategy includes pharmaceutical research, partnerships, and licensing. Lucid-MS, a treatment for demyelination, is the most advanced project. The company also pursues consumer wellness and royalty-based partnerships for diversified revenue. The WHO reports over 3 billion people live with neurological conditions, highlighting the market need.
Quantum BioPharma (QNTM) was featured in 'Men's Fitness' for its unbuzzd clinical trial, which showed promising early results. The study reported lower estimated blood alcohol concentration and improved alertness and headache symptoms in participants. The findings could have significant implications for the industry.
Quantum BioPharma (QNTM) signed a study agreement with Thermo Fisher for a Phase 2 trial of Lucid-MS, a drug for progressive MS. The FDA cleared the IND application in August 2026. Lucid-MS targets myelin protection, differing from existing MS treatments. The trial will assess safety, tolerability, and efficacy, but enrollment details are not yet announced.
Quantum BioPharma's Unbuzzd study, cited in Men’s Fitness, showed lower estimated BAC and improved alertness in 26 adults, though results were mixed and sample size was small. The company-sponsored, placebo-controlled trial requires larger trials for validation, according to the report.
Quantum BioPharma (QNTM) signed a study start-up agreement with Thermo Fisher Scientific for its Phase 2 Lucid-MS trial for multiple sclerosis, following FDA clearance. The trial will evaluate efficacy, safety, and tolerability. MS affects 2.8 million people globally, with the therapeutic market projected to exceed $38B by 2030, according to the company.
Quantum BioPharma (QNTM) announced that the U.S. District Court for the Southern District of New York consolidated its lawsuit and a class action against CIBC and RBC, alleging stock manipulation. The court appointed Grant & Eisenhofer as lead counsel. The lawsuit claims defendants used 'spoofing' techniques to manipulate Quantum's stock price between 2020 and 2024, harming shareholders.
